Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 20/20 | 0.66 |
| ▸ | F10 | P00742 | 17/20 | 0.66 |
| ▸ | F3 | P13726 | 17/20 | 0.66 |
| ▸ | F2 | P00734 | 15/20 | 0.66 |
| ▸ | F11 | P03951 | 10/20 | 0.66 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.64 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150980 | 0.90 | F7 (0.74) | F7F10F3F2F11 | |
| SCHEMBL7150990 | 0.90 | F7 (0.74) | F7F10F3F2F11 | |
| SCHEMBL7150985 | 0.90 | F7 (0.74) | F7F10F3F2F11 | |
| SCHEMBL5034393 | 0.88 | F7 (0.70) | F7F10F3F2F11 | |
| SCHEMBL3856774 | 0.86 | F7 (0.52) | F7F10F3F2F11 | |
| SCHEMBL7443963 | 0.85 | F7 (0.49) | F7F10F3F2F11 | |
| SCHEMBL5044585 | 0.84 | F7 (0.75) | F7F10F3F2PRSS1 | |
| SCHEMBL4333411 | 0.83 | F7 (0.49) | F7F10F3F2F11 | |
| SCHEMBL7142569 | 0.82 | F7 (0.73) | F7F10F3F2F11 | |
| SCHEMBL7142570 | 0.82 | F7 (0.73) | F7F10F3F2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594845-A4 | BENZENE ACETAMIDE COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7144895-B2 | Benzene acetamide compounds useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1594845-A2 | BENZENE ACETAMIDE COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040176375-A1 | Benzene acetamide compounds useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-09 | — | — | US | disclosed |
| WO-2004072102-A2 | BENZENE ACETAMIDE COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176375-A1 | Benzene acetamide compounds useful as serine protease inhibitors | CTRL, API5, PRSS1 | F7 575/4885F10 1140/4885F3 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.